Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

437
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
437
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

570
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
570
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

345
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
345
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

395
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
395
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

388
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
388
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

681
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
681

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated computational-based design of putative dual TrkA/TrkB agonists for Alzheimer's disease: pharmacophore modelling, docking, MM/GBSA, DFT and dynamics studies.

Frontiers in bioinformatics·2026
Same author

Molecular neurobiological insights on integrative role of Trk neurotrophic receptors and their small-molecule agonists in neurodegenerative conditions.

Experimental brain research·2026
Same author

Multifunctional quinoline-based hydrazones as promising antidiabetic agents: experimental and computational insights.

Bioorganic & medicinal chemistry letters·2026
Same author

Navigating the maze of Alzheimer's: nimodipine and pioglitazone combination in the spotlight through inhibition of P2X7 dependent NLRP3 inflammasome activation.

Inflammopharmacology·2026
Same author

Biopolymer Hydrogel-Based Nanocomposites Functionalized with Natural Products for Wound Dressings: Translational Advances in Drug Design, Development, and Therapeutic Wound Care.

Drug design, development and therapy·2026
Same author

Transcriptome sequencing (RNA-Seq) reveals non-coding pseudogene CDC27P9 role in cervical cancer.

Apoptosis : an international journal on programmed cell death·2026

Related Experiment Video

Updated: Nov 15, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

671

Glitazones, PPAR-γ and Neuroprotection.

Ashwini Prem Kumar1, Prabitha P2, B R Prashantha Kumar2

  • 1Department of Pharmacology, JSS College of Pharmacy, Ooty-643001, Tamilnadu, India.

Mini Reviews in Medicinal Chemistry
|March 5, 2021
PubMed
Summary

Peroxisome proliferator-activated receptor-gamma (PPAR-γ) activation by glitazones shows promise for neurodegenerative diseases. This strategy enhances neuroprotection by boosting PGC-1α signaling, improving antioxidant defenses and mitochondrial function.

Keywords:
PPAR-γconformational changescytokinesglitazonesmitochondrial biogenesisneuroprotection.

More Related Videos

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

39.2K
New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells
06:34

New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells

Published on: October 9, 2017

9.4K

Related Experiment Videos

Last Updated: Nov 15, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

671
Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

39.2K
New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells
06:34

New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells

Published on: October 9, 2017

9.4K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Peroxisome proliferator-activated receptor-gamma (PPAR-γ), a nuclear receptor, is implicated in neurodegenerative and metabolic disorders.
  • PPAR-γ activation upregulates its co-activator PGC-1α, influencing molecular events crucial for neurological health.
  • Dysfunctional PGC-1α expression is a key factor in the pathogenesis of major neurodegenerative diseases.

Purpose of the Study:

  • To review the role of PPAR-γ activation in neuroprotection.
  • To explore the mechanism of glitazone-mediated PPAR-γ activation and its impact on PGC-1α signaling.
  • To highlight the potential of this strategy for treating neurodegenerative conditions.

Main Methods:

  • Review of existing literature on PPAR-γ, PGC-1α, and glitazones in neurodegeneration.
  • Analysis of in silico studies investigating PPAR-γ dependent signaling pathways.
  • Examination of molecular mechanisms underlying PPAR-γ/PGC-1α interactions.

Main Results:

  • Ligand-dependent activation of PPAR-γ by glitazones can induce conformational changes, facilitating PGC-1α recruitment and complex formation.
  • This regulatory complex formation inhibits molecular pathways contributing to neurodegeneration.
  • In silico studies suggest glitazone-activated PPAR-γ/PGC-1α signaling enhances the antioxidant system, anti-inflammatory responses, and mitochondrial biogenesis.

Conclusions:

  • PPAR-γ activation by glitazones represents a promising therapeutic strategy for neurodegenerative diseases.
  • Enhancing the PPAR-γ/PGC-1α pathway offers neuroprotection by bolstering cellular defense mechanisms.
  • Further research and clinical trials are warranted to validate the therapeutic potential of novel glitazones.